TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates
Arndt MF, Koohestani DM, Chobrutskiy BI, Mihyu MM, Diaz M, Gozlan EC, Yeagley M, Zaman S, Roca AM, Blanck G. TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates. Human Immunology 2020, 81: 692-696. PMID: 32950267, DOI: 10.1016/j.humimm.2020.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAllelesBiomarkers, TumorDisease-Free SurvivalExomeGenes, T-Cell Receptor betaHead and Neck NeoplasmsHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensHumansKaplan-Meier EstimatePrognosisReceptors, Antigen, T-Cell, alpha-betaSurvival RateV(D)J RecombinationConceptsHuman papilloma virusHLA allele combinationsT cell receptorSurvival rateCervical cancerHLA allelesParticular human leukocyte antigen (HLA) allelesBetter disease-free survival rateCancer Genome Atlas (TCGA) headDisease-free survival ratesJ usageHuman leukocyte antigen (HLA) allelesFree survival rateOverall survival rateCancer survival ratesSpecific HLA allelesDistinct overall survival ratesNeck cancer datasetPapilloma virusIndependent associationAntigen presentationAntigen allelesViral infectionHLAExome files